Safety information of tacrolimus: Present and future;Datos de seguridad del tacrolimus: Presente y futuro

Actas Dermo-Sifiliograficas

Volumn 99, Issue SUPPL.2, 2008, Pages 19-25

  Sanchez Perez J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Atrophy; Cutaneous infection; Experimental studies; Irritation; Lymphoma; Melanoma; Nonmelanoma skin cancer; Posttrasplant lymphoproliferative disease; Tacrolimus

Indexed keywords

TACROLIMUS;

APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; ATOPIC DERMATITIS; BURNING SENSATION; DRUG INFORMATION; DRUG SAFETY; HUMAN; LYMPHOMA; NONHUMAN; PRURITUS; REVIEW; SKIN CANCER;

EID: 39049123632     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/s0001-7310(08)76207-0     Document Type: Review

References (59)

1. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol. 2002;27:555-61.
2. U.S. Food and Drugs Administration. Anonymous: New warnings for two eczema drugs [consultado el 7 de julio de 2007]. Disponible en: http://www. fda.gov/fdac/departs/2006/206_upd.html.
3. European Medicines Agency. Cautious use of Protopic/ Protopy and Elidel [consultado el 7 de julio de 2007]. Disponible en: http://www.emea.europa.eu/ pdfs/general/direct/pr/9888206en.pdf.
4. Reitamo S, Wollenberg A, Schöpf E, Perrot JL, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000;136:999-1006.
5. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2001;44 Suppl:S17-27.
6. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44 Suppl:S47-57.
7. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44 Suppl:S58-64.
8. Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44 Suppl:S39-46.
9. Nakahara T, Koga T, Fukagawa S, Uchi H, Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol. 2004;31:524-8.
10. Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, et al. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53 Suppl 2:S186-94.
11. Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203-21.
12. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330:516.
13. Iskedjian M, Piwko C, Shear NH, Langley RG, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. Am J Clin Dermatol. 2004;5:267-79.
14. Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, et al. US Tacrolimus Ointment Study Group. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics. 2005;116:e334-42.
15. Milingou M, Antille C, Sorg O, Saurat JH, Lubbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol. 2004;140:1542-4.
16. Calza AM, Lubbe J. Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication. Br J Dermatol. 2005;152:569.
17. Knight AK, Boxer M, Chandler MJ. Alcohol-induced rash caused by topical tacrolimus. Ann Allergy Asthma Immunol. 2005;95:291-2.
18. Shaw DW, Eichenfield LF, Shainhouse T, Maibach HI. Allergic contact dermatitis from tacrolimus. J Am Acad Dermatol. 2004;50:962-5.
19. Reitamo S, Rissanen J, Remitz A, Granlund H, Erkko P, Elg P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-8.
20. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150:1174-81.
21. Sánchez-Pérez J. Pimecrolimus/tacrolimus tópicos y riesgo de cáncer. Actas Dermosifiliogr. 2007;98:312-7.
22. U.S. Food and Drug Administration. Astellas Pharma (tacrolimus) ointment 0.03% and 0.1% briefing document, (6/2006) [Consultado el 7 de julio de 2007]. Disponible en: http://www.fda.gov/cder/foi/label/2006/050777s012lbl.pdf.
23. McNeill AM, Koo JY. "Unknown Risks" of non-steroid topical medications for atopic dermatitis. Int J Dermatol. 2007;46:656-8.
24. Berger TG, Duvic M, Van Voorhees AS, Van Beek MJ, Frieden IJ. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818-23.
25. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2005;19:663-71.
26. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer. 1997;80:1141-50.
27. Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation. 1999;68:997-1003.
28. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl. 2000;6:253-62.
29. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211:174-87.
30. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, et al. American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115:1249-53.
31. Carroll CL, Fleischer AB Jr. Tacrolimus: Focusing on atopic dermatitis. Drugs Today. 2006;42:431-9.
32. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006;6:270-4.
33. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol. 2005;153:701-5.
34. Papp KA, Breuer K, Meurer M, Ortonne JP, Potter PC, de Prost Y, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52:247-53.
35. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53 Suppl 2:S206-13.
36. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
37. Ellingsen AR, Sorensen FB, Larsen JO, Deleuran MS, Thestrup-Pedersen K. Stereological quantification of lymphocytes in skin biopsies from atopic dermatitis patients. Acta Derm Venereol. 2001;81:258-62.
38. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282-9.
39. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117:e118-28.
40. Koo JY, Fleischer AB Jr, Abramovits W, Pariser DM, McCall CO, Horn TD, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005;53 Suppl 2:S195-205.
41. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997 18;337:816-21.
42. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38:69-76.
43. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003;139:1184-6.
44. Harper J, Smith C, Rubins A, Green A, Jackson K, Zigure S, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124:695-9.
45. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137:747-50.
46. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003;207:37-42.
47. Becker JC, Houben R, Vetter CS, Brocker EB. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer. 2006;11:6-7.
48. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol. 2005;152:183-5.
49. Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reprod Med. 2007;52:329-31.
50. Scurry JP, Vanin K. Vulvar squamous cell carcinoma and lichen sclerosus. Australas J Dermatol. 1997;38 Suppl 1:S20-5.
51. Mignogna MD, Lo Muzio L, Lo Russo L, Fedele S, Ruoppo E, Bucci E. Clinical guidelines in early detection of oral squamous cell carcinoma arising in oral lichen planus: a 5-year experience. Oral Oncol. 2001;37:262-7.
52. Bunker CB, Neill S, Staughton RC. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. Arch Dermatol. 2004;140:1169.
53. U.S. Food and Drug Administration. Alerts for healthcare professionals tacrolimus (marketed as protopic), March 2005. [Consultado 7 de julio de 2007]. Disponible en: http://www.fda.gov/cder/drug/infoSheets/HCP/ProtopicHCP.htm.
54. Naylor M, Elmets C, Jaracz E, Rico JM. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Dermatolog Treat. 2005;16:149-53.
55. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214:289-95.
56. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633-7.
57. Paller A, Brinkmann W, Joyce Rico M. APPLES: A prospective pediatric longitudinal evaluation to assess the long-term safety of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2007;56:2 Suppl 2:AB3.
58. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808-16.
59. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47:1-17.